- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06783309
CNP-103 hos ungdom og voksne i alderen 12-35 år med nylig diagnostisert (innen 6 måneder) stadium 3 type 1 diabetes (T1D)
En fase 1b/2a dobbeltblind, placebokontrollert studie for å evaluere sikkerheten, tolerabiliteten, farmakodynamikken og effekten av CNP-103 hos forsøkspersoner i alderen 12-35 år med nylig oppstått stadium 3 type 1-diabetes
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: COUR Trial Information
- Telefonnummer: 949-922-0092
- E-post: clinicaltrials@courpharma.com
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85710
- Rekruttering
- Wake Research - Tucson
-
Ta kontakt med:
- Namrata Oza
- Telefonnummer: 520-210-7930
- E-post: noza@wakeresearch.com
-
Hovedetterforsker:
- David Alster
-
Tucson, Arizona, Forente stater, 85716
- Rekruttering
- Liver Institute PLLC
-
Ta kontakt med:
- Nicolette Brown
- Telefonnummer: 520-209-1757
- E-post: nbrown@liverinstitutepllc.org
-
Hovedetterforsker:
- Neda Ebrahimi
-
-
California
-
Newport Beach, California, Forente stater, 92663
- Rekruttering
- Hoag Memorial Hospital
-
Ta kontakt med:
- Brittany Dennis
- Telefonnummer: 949-764-6896
- E-post: brittany.dennis@hoag.org
-
Hovedetterforsker:
- David Ahn
-
Ta kontakt med:
- Cadence Cooper
- Telefonnummer: 949-764-6896
- E-post: cadence.cooper@hoag.org
-
San Diego, California, Forente stater, 92123
- Rekruttering
- Rady Children's Hospital San Diego
-
Ta kontakt med:
- Carla Logan
- Telefonnummer: 858-966-8400
- E-post: clogan1@rchsd.org
-
Ta kontakt med:
- Angela Lam
- Telefonnummer: 858-966-8400
- E-post: alam@rchsd.org
-
Hovedetterforsker:
- Carla Demeterco-Berggren
-
Walnut Creek, California, Forente stater, 94598
- Rekruttering
- Diablo Clinical Research
-
Ta kontakt med:
- Catherine Morimoto
- E-post: cmorimoto@diabloclinical.com
-
Hovedetterforsker:
- Mark Christiansen
-
Ta kontakt med:
- Drew Jaffe
- Telefonnummer: 9259307287
- E-post: djaffe@diabloclinical.com
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- Barbara Davis Center for Childhood Diabetes
-
Ta kontakt med:
- Hali Broncucia
- Telefonnummer: 3037247526
- E-post: hali.broncucia@cuanschutz.edu
-
Ta kontakt med:
- Fatima Tensun
- E-post: fatima.tensun@cuanschutz.edu
-
Hovedetterforsker:
- Taylor Triolo
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33907
- Rekruttering
- Southwest General Healthcare Center
-
Ta kontakt med:
- Daniela Pargas
- Telefonnummer: 239-931-3368
- E-post: daniela@swghealthcare.com
-
Ta kontakt med:
- Sandra Perez
- Telefonnummer: 239-931-3368
- E-post: sandra@swghealthcare.com
-
Hovedetterforsker:
- Orlando Fernandez
-
Gainesville, Florida, Forente stater, 32610
- Rekruttering
- University of Florida
-
Ta kontakt med:
- Sarah Peeling
- Telefonnummer: 352-273-5275
- E-post: smpeeling@peds.ufl.edu
-
Hovedetterforsker:
- Timothy Foster
-
Ta kontakt med:
- Magali Jorand-Fletcher
- Telefonnummer: 352-294-5760
- E-post: magali20@ufl.edu
-
Hialeah, Florida, Forente stater, 33012
- Rekruttering
- Evolution Research Center
-
Ta kontakt med:
- Ana Fernandez
- Telefonnummer: 786-708-6008
- E-post: afernandez@evolutionresearchcenter.com
-
Ta kontakt med:
- Jany Fundora
- E-post: jfundora@evolutionresearchcenter.com
-
Hovedetterforsker:
- Andrea Sosa-Melo
-
Jacksonville, Florida, Forente stater, 32207
- Rekruttering
- Nemours Children's Health
-
Hovedetterforsker:
- Larry Fox
-
Ta kontakt med:
- Jennifer Pann
- Telefonnummer: 904-776-2810
- E-post: jennifer.pann@nemours.org
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami
-
Hovedetterforsker:
- David Baidal
-
Ta kontakt med:
- Danay Saavedra
- Telefonnummer: 305-243-6616
- E-post: dxs4415@med.miami.edu
-
Ta kontakt med:
- Jhanvi Doshi
- Telefonnummer: 305-243-3306
- E-post: jxd4468@med.miami.edu
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- DY Professional Research Center
-
Hovedetterforsker:
- Soroush Aghigh
-
Ta kontakt med:
- Yesenia Escarpio
- Telefonnummer: 3059828331
- E-post: yescarpio@dymedicalresearch.com
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- University of South Florida
-
Hovedetterforsker:
- Henry Rodriguez
-
Ta kontakt med:
- Elizabeth Dunn
- Telefonnummer: 813-974-4886
- E-post: eadunn3@usf.edu
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University
-
Ta kontakt med:
- Meaza Girmay
- Telefonnummer: 404-778-6382
- E-post: meaza.girmay@emory.edu
-
Hovedetterforsker:
- Michael Hughes
-
Atlanta, Georgia, Forente stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta
-
Hovedetterforsker:
- Kristina Cossen
-
Ta kontakt med:
- Jordyn Turner
- Telefonnummer: 404-785-3690
- E-post: Jordyn.Turner@choa.org
-
Atlanta, Georgia, Forente stater, 30318
- Rekruttering
- Atlanta Diabetes Association
-
Ta kontakt med:
- Amanda Maxson
- Telefonnummer: 404-355-4393
- E-post: amaxson@atlantadiabetes.com
-
Hovedetterforsker:
- Carson Womack
-
-
Idaho
-
Idaho Falls, Idaho, Forente stater, 83404
- Rekruttering
- Rocky Mountain Diabetes and Osteoporosis Center
-
Ta kontakt med:
- Joann Malone
- Telefonnummer: 208-528-9650
- E-post: joann.malone@rmclinicalresearch.com
-
Ta kontakt med:
- Ben Houston
- Telefonnummer: 208-525-3739
- E-post: ben.houston@rmclinicalresearch.com
-
Hovedetterforsker:
- Joshua Smith
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern University
-
Hovedetterforsker:
- Grazia Aleppo
-
Ta kontakt med:
- Stefanie Hermann
- Telefonnummer: 312-926-8693
- E-post: s-herrmann@northwestern.edu
-
Ta kontakt med:
- Evelyn Fronczyk
- E-post: evelyn.guevara@northwestern.edu
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Ann & Robert H. Lurie Children's Hospital
-
Ta kontakt med:
- Rohin Sagar
- Telefonnummer: 312-227-9403
- E-post: rsagar@luriechildrens.org
-
Ta kontakt med:
- Maddie Lamphear
- Telefonnummer: 312-227-9403
- E-post: mlamphear@luriechildrens.org
-
Hovedetterforsker:
- Naomi Fogel
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
Hovedetterforsker:
- Gabriel Uwaifo
-
Ta kontakt med:
- Rebecca Owens
- Telefonnummer: 217-545-7321
- E-post: rowens29@siumed.edu
-
Ta kontakt med:
- Katharine Blancett
- Telefonnummer: 217-545-7799
- E-post: kblancett37@siumed.edu
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Riley Hospital for Children- Indiana University
-
Ta kontakt med:
- Nate De Jong
- Telefonnummer: 317-278-4874
- E-post: nadejong@iu.edu
-
Hovedetterforsker:
- Linda DeMeglio
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21229
- Rekruttering
- Barry J. Reiner, MD, LLC
-
Ta kontakt med:
- Lee Bromberger
- Telefonnummer: 410-646-4009
- E-post: reinerstudy.lee@gmail.com
-
Hovedetterforsker:
- Barry Reiner
-
Ta kontakt med:
- Ashley Hargrove
- E-post: reinerstudy.ashley2@gmail.com
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Joslin Diabetes Center
-
Hovedetterforsker:
- Jason Gaglia
-
Ta kontakt med:
- Abigail Coryell
- Telefonnummer: 617-309-1909
- E-post: acoryell@joslin.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan
-
Ta kontakt med:
- Adam Neidert
- Telefonnummer: 734-615-0539
- E-post: aneidert@med.umich.edu
-
Hovedetterforsker:
- Elif Oral
-
Ta kontakt med:
- Carman Richison
- Telefonnummer: 734-615-6258
- E-post: caaguiar@med.umich.edu
-
Bloomfield Township, Michigan, Forente stater, 48302
- Rekruttering
- Embassy Research Network
-
Ta kontakt med:
- Zander Minano
- Telefonnummer: 248-622-4083
- E-post: zminano@embassyresearch.com
-
Hovedetterforsker:
- George Grunberger
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55454
- Rekruttering
- University of Minnesota
-
Ta kontakt med:
- Veronica Jones-Carr
- Telefonnummer: 612-625-9709
- E-post: jone2678@umn.edu
-
Ta kontakt med:
- Kali Johnson
- E-post: joh13933@umn.edu
-
Hovedetterforsker:
- Antoinette Moran
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Rekruttering
- Children's Mercy Hospital
-
Ta kontakt med:
- Ashley Parks
- Telefonnummer: 816-302-8419
- E-post: anparks@cmh.edu
-
Hovedetterforsker:
- Wayne Moore
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Hovedetterforsker:
- Janet McGill
-
Ta kontakt med:
- Elizabeth Sellitto
- Telefonnummer: 314-362-6821
- E-post: esellitto@wustl.edu
-
-
New York
-
Buffalo, New York, Forente stater, 14203
- Rekruttering
- UBMD Pediatrics - University of Buffalo
-
Ta kontakt med:
- Amanda House
- Telefonnummer: 716-323-0075
- E-post: ahouse@upa.chob.edu
-
Hovedetterforsker:
- Lucy Mastrandrea
-
New York, New York, Forente stater, 10017
- Rekruttering
- NYU Langone Diabetes & Endocrine Associates
-
Ta kontakt med:
- Amanda Baly
- Telefonnummer: 212-637-7000
- E-post: Amanda.Baly@nyulangone.org
-
Hovedetterforsker:
- Ramachandra Naik
-
New York, New York, Forente stater, 10016
- Rekruttering
- Hassenfield Children's Hospital
-
Ta kontakt med:
- Jeniece Ilkowitz
- Telefonnummer: 212-263-9910
- E-post: jeniece.ilkowitz@nyulangone.org
-
Hovedetterforsker:
- Mary Gallagher
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University
-
Ta kontakt med:
- Kia Gaskins
- Telefonnummer: 919-613-0234
- E-post: kiah.gaskin@duke.edu
-
Hovedetterforsker:
- Jennifer Green
-
Greenville, North Carolina, Forente stater, 27834
- Rekruttering
- Physicians East, PA
-
Hovedetterforsker:
- Mark Warren
-
Ta kontakt med:
- Kirsten Goff
- Telefonnummer: 252-413-6299
- E-post: ktaylor@physicianseast.com
-
Raleigh, North Carolina, Forente stater, 27612
- Rekruttering
- Wake Research - Raleigh
-
Ta kontakt med:
- LaTosha Gonzalez
- Telefonnummer: 9192142514
- E-post: lgonzalez@wakeresearch.com
-
Ta kontakt med:
- Fabricio Nunez
- E-post: fnunez@wakeresearch.com
-
Hovedetterforsker:
- Khushbu Chandarana
-
Smithfield, North Carolina, Forente stater, 27577
- Rekruttering
- Superior Clinical Research
-
Hovedetterforsker:
- Clifford Curtis
-
Ta kontakt med:
- Briana White
- Telefonnummer: 9199388058
- E-post: briana@superiorclinicalresearch.com
-
Ta kontakt med:
- Martha Dockery
- E-post: martha@superiorclinicalresearch.com
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- University Hospitals Cleveland Medical Center
-
Ta kontakt med:
- Quiana Howard
- Telefonnummer: 216-286-0021
- E-post: Quiana.Howard@UHhospitals.org
-
Ta kontakt med:
- Jennie Phan
- Telefonnummer: 216-286-7454
- E-post: Jennie.Phan@Uhhospitals.org
-
Hovedetterforsker:
- Betul Hatipoglu
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37411
- Rekruttering
- University Diabetes & Endocrine Consultants
-
Hovedetterforsker:
- David Huffman
-
Ta kontakt med:
- Gina Harris
- Telefonnummer: 423-265-3561
- E-post: gharris@drhuffman.com
-
Memphis, Tennessee, Forente stater, 38105
- Rekruttering
- Le Bonhuer Children's
-
Ta kontakt med:
- Christine Watkins
- Telefonnummer: 901-287-5579
- E-post: christine.watkins@lebonheur.org
-
Hovedetterforsker:
- Ramin Alemzadeh
-
-
Texas
-
Austin, Texas, Forente stater, 78749
- Rekruttering
- Texas Diabetes & Endocrinology
-
Hovedetterforsker:
- Jean Chen
-
Ta kontakt med:
- Emmanuel Lopez
- Telefonnummer: 5123343505
- E-post: elopez@texasdiabetes.com
-
Ta kontakt med:
- Olivia Johnson
- E-post: ojohnson@texasdiabetes.com
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- M3 Wake Research - Dallas
-
Ta kontakt med:
- Vicki Martinez
- Telefonnummer: 469-297-3074
- E-post: vmartinez@wakeresearch.com
-
Hovedetterforsker:
- Carlos Arauz-Pacheco
-
Humble, Texas, Forente stater, 77346
- Rekruttering
- Accurate Clinical Research, Inc
-
Hovedetterforsker:
- Brian Chou
-
Ta kontakt med:
- Soamy Rivera
- E-post: srivera@accurateclinicalresearch.com
-
Ta kontakt med:
- Valerie Blanco
- Telefonnummer: 2817603930
- E-post: vblanco@accurateclinicalresearch.com
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Diabetes & Glandular Disease (DGD) Clinic, P.A.
-
Hovedetterforsker:
- Mark Kipnes
-
Ta kontakt med:
- Bobbi Hernandez
- Telefonnummer: 1088 2106148612
- E-post: bobbi.hernandez@dgdclinic.com
-
Ta kontakt med:
- Monique Johnson
- E-post: monique.johnson@dgdclinic.com
-
Waxahachie, Texas, Forente stater, 75165
- Rekruttering
- TopLine Clinical, Inc
-
Ta kontakt med:
- Lacey Powers
- Telefonnummer: 972-965-3247
- E-post: lacey@toplineclinical.com
-
Hovedetterforsker:
- Stephen Mueller
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Rekruttering
- Benaroya Research Institute
-
Ta kontakt med:
- Natalie Clary
- Telefonnummer: 206-342-6963
- E-post: nclary@benaroyaresearch.org
-
Ta kontakt med:
- Erica Bourget
- Telefonnummer: 206-341-8997
- E-post: EBourget@benaroyaresearch.org
-
Hovedetterforsker:
- Kurt Griffin
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- University of Washington Diabetes Institute
-
Ta kontakt med:
- Dori Khakpour
- Telefonnummer: 206-945-4965
- E-post: dorik@uw.edu
-
Hovedetterforsker:
- Irl Hirsch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Participants who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
-
Men and non-pregnant, non-breast-feeding women ages 12-35 years inclusive.
-
Documented diagnosis of Stage 3 T1D within 180 days prior to study enrollment according to American Diabetes Association (ADA) criteria.
-
Participants must be on standard of care diabetes management including insulin therapy as a routine and also consisting of a nutrition plan, regular exercise, or other relevant specialty care as required on a patient-by-patient basis.
-
Participants with a peak stimulated C-peptide of >0.2 nmol/L measured from a screening mixed meal tolerance test (MMTT).
-
Participants with an episode of diabetic ketoacidosis (DKA) must have a MMTT performed no sooner than 2 weeks after resolution of the DKA event to have a qualifying C-peptide reading.
-
Participants on systemic corticosteroids or any medication used to treat the symptoms of T1D (other than insulin) must undergo a washout period of at least two weeks prior to enrollment and must agree to use a non-steroid alternative throughout the trial, if necessary, for any disorder requiring corticosteroids. In addition, participants must be on a stable dose of any other medications, other than insulin, for a minimum of 1 month prior to enrollment and must agree not to increase their dose from the Screening Visit through the End of Study Visit unless reviewed and approved by the medical monitor and the principal investigator.
-
Female participants of non-childbearing potential (e.g., surgical sterilization, no menses for a year).
-
Women of childbearing potential (WOCBP) who have agreed not to become pregnant during the study, have a negative pregnancy test at Screening Visit, and agree to use 1 highly effective form of birth control starting at initial screening and continuing throughout the entire study to Day 365.
-
Female participants who agree to not breastfeed starting at initial Screening and throughout the entire study to Day 365.
-
Female participants who agree to not donate ova, including autologous, starting at initial Screening and throughout the entire study to Day 365.
-
Male participant and with a spouse or partner of childbearing potential, who themselves and their spouse or partner agree to practice an effective form of birth control as discussed with the study doctor or study staff starting at Screening and throughout the entire study to Day 365.
-
Participants must weigh >35 kg at Screening for Cohort 1 (100 mg) and Cohort 2 (300 mg); participants must weigh >50 kg at Screening for Cohort 3 (600 mg).
-
Body mass index (BMI):
- Participants 12-17 years: BMI Z-Score within 5th and 95th percentile based on participant's age (e.g., Baylor College of Medicine Age-based Pediatric Growth Reference Charts: BMI Z-Score and Percentile Calculator)
- Participants 18-35 years: 18.0-30.0 (not inclusive)
Exclusion Criteria:
-
Participants unable to comply with prohibited medication outlined in the protocol.
-
Exclusion of additional immunomodulation will be at the discretion of the Medical Monitor and study site Investigator.
-
Participants with a history of tuberculosis or positive Quantiferon test.
-
Participants who received vaccinations in the following time frame:
- Any live vaccine within 28 days prior to Screening.
- Any subunit vaccine within 14 days prior to Screening.
- Any COVID-19 vaccine series within 14 days prior to Screening.
- Any other planned vaccine starting 14 days prior to Screening and through study Day 90 and 1 week after. (Note: The annual influenza vaccine is not an exclusion criterion.)
-
Known or suspected acute infection, including COVID-19 at the time of Screening or within 2 weeks prior to Screening. After confirmed recent COVID-19 infection, a minimum of 2 weeks of recovery post-acute infection is required.
-
Participants with Screening laboratory test results that are outside the normal limits and considered by the Investigator to be clinically significant.
-
Participants with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at Screening.
-
Participants with a history of or currently active immune disorders other than T1D (including autoimmune disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the participant's participation in this study.
-
Participants with a clinical history of significant cardiovascular disease in the past 12 months.
-
Participants with a complication or medical history of malignant tumor, other than basal cell or squamous cell carcinomas of the skin.
-
Participants who, in the Investigator's opinion, will be unable to adhere to study visits and procedures.
-
Participants who have received investigational therapy other than CNP-103 within 28 days or 5 half-lives, whichever is longer, prior to Screening.
-
Participants with any known active condition which, in the Investigator's opinion, makes the participant unsuitable for study participation.
-
Known sensitivity to any components of CNP-103.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Adult Cohort 1 (100 mg CNP-103)
Three (3) IV administrations of CNP-103 (100 mg) on Days 1, 8, and 90 |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
|
Eksperimentell: Adult Cohort 2 (300 mg CNP-103)
Three (3) IV administrations of CNP-103 (300 mg) on Days 1, 8, and 90 |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
|
Eksperimentell: Adult Cohort 3 (600 mg CNP-103)
Three (3) IV administrations of CNP-103 (600 mg) on Days 1, 8, and 90 |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
|
Eksperimentell: Adolescent Cohort 1 (100 mg CNP-103)
Three (3) IV administrations of CNP-103 (100 mg) on Days 1, 8, and 90 |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
|
Eksperimentell: Adolescent Cohort 2 (300 mg CNP-103)
Three (3) IV administrations of CNP-103 (300 mg) on Days 1, 8, and 90 |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
|
Eksperimentell: Adolescent Cohort 3 (600 mg CNP-103)
Three (3) IV administrations of CNP-103 (600 mg) on Days 1, 8, and 90 |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
|
Eksperimentell: Expansion Cohort
Dosing for the Expansion Cohort will be determined from Escalation Phase results |
CNP-103
Andre navn:
0.9% sodium chloride for injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety
Tidsramme: Day 1 Through Day 365
|
Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs), MedDRA 28.1 (CTCAE v. 5.0) or current |
Day 1 Through Day 365
|
|
Immune Safety
Tidsramme: Day 1 Through Day 365
|
Serum Cytokines: IL-1β, TNF-α, IL-6, MCP-1, MIP-1α, IFN-γ, IL-4, IL-10 |
Day 1 Through Day 365
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CNP-103-CL-201
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .